Overview

The condition known as neuromyelitis optica (NMO), which can also be referred to as Devic disease and neuromyelitis optica spectrum disorder (NMOSD), is a rare chronic condition of the central nervous system that causes inflammation in the nerves of the eye, the spinal cord. It is an autoimmune disease, which means that the immune system wrongly attacks certain areas of the central nervous system. This primarily occurs in the spinal cord and optic nerves, which link the retina of the eye with the brain. However, it can also happen in the brain

The condition could develop following an infection. It might also be connected to another autoimmune disorder. Irregular antibodies attach to proteins within the central nervous system, resulting in harm.

Multiple sclerosis (MS) is frequently misdiagnosed as neuromyelitis optica, or it is thought to be a subtype of MS. NMO, however, is a different disease.

One or both eyes may become blind as a result of neuromyelitis optica, which can also result in arm or leg weakness or paralysis , and painful spasms. In addition, spinal cord damage can result in loss of sensation, uncontrollable vomiting, hiccups, and bladder or bowel issues. Children may experience comas, seizures, or confusion.

Relapses are frequent, and preventing recurring attacks is essential to avoiding disability. Although neuromyelitis optica flareups may be treatable, they can sometimes be severe enough to result in permanent vision loss and mobility issues.

Symptoms

NMO creates symptom attacks,which refers to intermittent (come and go) symptoms. Attacks may last for several days or even months. These types of attacks are frequently severe and can result in permanent damage. When this occurs, even after an attack has ended, the effects could still last

Three categories of NMO symptoms can be identified and include

  • Optic neuritis: The optic nerve, which connects their eyes to their brain, receives signals from the eyes as they gather light from their environment. The patient’s perception of sight is then provided by the brain’s processing of those signals. Optic neuritis leads to inflammation of the optic nerve, resulting in its swelling. Given the limited space within the head, this swelling can exert excessive pressure on the optic nerve.

One or both of the optic nerves are inflamed, which causes these symptoms.

    • Eye pain: When the patient moves affected eye(s), this frequently takes place or becomes worse.
    • Blurry vision: When the patient is physically active, this symptom could worsen.
    • Partial or complete vision loss: Patient may experience complete or partial blindness in one eye (loss of the center of the field of vision is one example). Their vision may also become dim or they may have problems seeing colors.
    • Problem seeing in low light: Certain nighttime activities, including driving, may become challenging
  • Myelitis: Inflammation of the spinal cord is known as myelitis. The spinal cord or surrounding spinal nerves may become compressed as a result of that swelling brought on by the inflammation. As a result, nerve signals that try to flow through the affected region may be partially or completely blocked

The presentation of myelitis symptoms is contingent upon the location of the inflammation and which segments of the spinal cord or spinal nerves are impacted. Common symptoms of myelitis include:

    • Muscle weakness or paralysis: Body parts farther down from the damaged spinal nerves and/or below the affected region of the spinal cord are affected. This may make it difficult to use both arms and hands, or it may make it difficult to stand or walk. Myelitis can cause paralysis or weakening in the breathing muscles if it affects the cervical spinal cord, which is the portion of the spinal cord in the back of the neck.
    • Spasticity: This occurs when the muscles contract independently due to a lack of control signals from the brain. As a result, muscles start to flex or tighten uncontrollably.
    • Pain: Myelitis can put pressure on the spinal cord and create pain. The swelling itself may cause the pain, or it may make the damaged nerves send pain signals incorrectly.
    • Incontinence: Their ability to regulate when they pee (urinate) or poop (defecate) can be affected by myelitis, which can interfere with the nerve signals that control their bladder and bowels. Bowel or urine incontinence may result from those muscles being uncontrolled.
    • Sexual dysfunction: The nerve signals that regulate the sexual organs or sexual activities can be interfered with by myelitis.
  • Brain function disruptions: It is more typical for people with multiple sclerosis (MS) to experience alterations in their brain, although this is less typical for people with NMO. When it occurs, it may interfere with how their brain manages particular bodily functions. These disturbances can result in serious or even dangerous issues if they affect the brainstem or hypothalamus.

The brainstem may be affected by NMO, which might result in the following symptoms:

    • Hiccups that is uncontrollable.
    • Itching (pruritus) that is uncontrollable.
    • Unexplained nausea and vomiting 
    • Hearing loss.
    • Double vision (diplopia
    • Uncontrollable eye movements (nystagmus) 
    • Facial paralysis (palsy).
    • Dizziness or vertigo.
    • Difficulty with balance or coordination (ataxia).
    • Trigeminal neuralgia (nervebased pain in the face)

The hypothalamus manages autonomic body processes. When NMO affects it, it can lead to disruptions in other bodily systems. A notable instance of this is NMO with narcolepsy.

Causes

Our understanding of NMO’s causes and mechanisms remains limited, and experts have only been able to offer partial explanations for its occurrence. Their knowledge is grounded in the following factors, although uncertainties persist:

  • Immune system malfunctions: As an autoimmune disorder, NMO results when the body’s immune system incorrectly targets a body part. In this instance, it affects the spinal cord and/or optic nerves.

NMO has two recognized autoimmune forms:

    • Aquaporin4 (AQP4) antibodies: A protein called AQP4 is present on the surface of several cells in the nervous system. Its function is to transport water into and out of cells. Unintentionally instructing the immune system to attack this protein, AQP4 antibodies harm the cells that have it on their surface. AQP4 antibodies are found in the blood of more than 80% of NMO patients.
    • Myelin oligodendrocyte glycoprotein (MOG) antibodies: MOG is a protein responsible for the formation and upkeep of the myelin sheath covering neurons. The myelin sheathing on the neurons is disrupted when MOG antibodies wrongly instruct the immune system to attack this protein. This antibody is present in the blood of about 6.5% of NMO patients.

These immune system irregularities predominantly occur for reasons that remain largely unidentified. Nevertheless, available data implies a potential link between these malfunctions and previous infections.

Currently, experts cannot ascertain the cause of NMO in individuals lacking AQP4 or MOG antibodies, constituting approximately 13.5% of those affected by this condition. These cases are categorized as idiopathic,signifying that they occur for reasons that remain unknown.

  • Other autoimmune or inflammatory conditions: NMO can occur on its own, although it is more common in persons who also have autoimmune or inflammatory diseases. Before researchers can conclude that these circumstances can either cause or contribute to NMO, more investigation is required.

These conditions include may include systemic lupus erythematosus (SLE), celiac disease, Sjogrens syndrome, disease, sarcoidosis, myastenia gravis, or antiphospolipid syndrome

  • Genetics: Genetic factors may contribute to NMO, according to experts. The fact that people of particular racial or ethnic backgrounds are more likely to have this medical condition is one reason they suspect it. One such factor is that 3% of NMO cases include members of the same family. Although there is no proof that NMO can be passed down through the family, there may be hereditary variables that make NMO more likely to occur.

Risk factors

The following factors increase the risk in developing NMO.

  • Age: People between the ages of 30 and 40 are typically affected. NMO in children is extremely rare, accounting for approximately 5% of occurrences.
  • Gender: Women make up 80% to 90% of cases of NMO, making them the group most likely to be affected.
  • Race: NMO can occur in persons of all racial and ethnic backgrounds, but it doesn’t do so equally across all groups. People of African origin, particularly those from the African Caribbean, are more likely to experience NMO.

Diagnosis

The healthcare provider conducts a thorough examination in order to exclude other nervous system disorders with signs and symptoms that resemble neuromyelitis optica. In 2015, the International Panel for the Diagnosis of NMO introduced criteria for diagnosing this condition.

  • Physical and neurological examination: A healthcare provider often does a physical exam, evaluates the patient’s medical history, and looks for symptoms to identify the condition. The movements, muscle power, coordination, sensation, memory, thinking, vision, and speech are all examined by a neurologist. The eye examination might involve an ophthalmologist.
  • Imaging test: A thorough image of the brain, optic nerves, and spinal cord is produced by this imaging test using a magnetic field and radio waves. Lesions or damaged regions of the brain, optic nerves, or spinal cord may be noticable to the healthcare provider.
  • Blood tests: The aquaporin4immunoglobulin G, often known as AQP4IgG antibody, may be tested for in the blood by a healthcare provider. This examination distinguishes between NMO and MS. This test helps in the early detection of NMO.

Relapses can be identified using additional biomarkers such serum glial fibrillary acidic protein (GFAP) and serum neurofilament light chain. Another inflammatory condition that resembles NMO may be found with a myelin oligodendrocyte glycoprotein immunoglobulin G (MOGIgG) antibody test.

  • Lumbar puncture (spinal tap): In order to remove a small amount of spinal fluid during this test, the neurologist must inject a needle into the lower back. Immune cells, proteins, and antibodies are measured in the fluid using this test to determine their amounts. By using this test, NMO and MS may be identified.

During NMO episodes, the spinal fluid may exhibit extremely high white blood cell counts. Although it doesn’t always happen, this is more amount than what is often seen with MS.

  • Stimuli response test: A test known as the evoked potentials test or evoked response test is performed to find out how well the brain reacts to stimuli like sounds, sights, or touch. Electrodes are affixed to the scalp and, in certain instances, to the earlobes, neck, arm, leg, and back. The electrodes’ equipment is used to record the brain’s reactions to stimuli. These examinations help in the discovery of lesions or damaged regions in the brain, spinal cord, optic nerve, or brainstem.
  • Optical coherence tomography: This examination evaluates retinal nerve and measures its thickness. Compared to persons with MS, patients with an inflamed optic nerve from NMO experience more severe vision loss and retinal nerve thinning. 

Treatment

Although there is currently no established cure for NMO, successful management strategies can occasionally lead to sustained periods of remission. Treatment for NMO primarily focuses on therapies aimed at reversing existing symptoms and preventing future attacks.

  • Reverse recent symptoms: A corticosteroid medication like methylprednisolone may be administered by a healthcare provider in the early stages of an NMO episode. It is administered by an arm vein. The medication is typically given for around five days before being gradually reduced off over several days.

In place of or in addition to steroid medication, plasma exchange is frequently suggested as the first or second line of treatment. During this operation, a little amount of blood is drawn from the patient, and plasma and blood cells are mechanically separated. The blood is then reintroduced to the body after the blood cells have been combined with a replacement solution. This procedure can clean the blood and remove dangerous substances.

  • Prevent the future attacks: In order to stop further NMO episodes and relapses, the healthcare provider may advise the patient to take a low dose of corticosteroids.
  • Reduce the relapses: Clinical trials have demonstrated the efficacy of monoclonal antibodies in lowering the risk of NMO relapses. Adult relapses can be treated with eculizumab, satralizumab, and inebilizumab.

Clinical trials have also demonstrated the effectiveness of rituximab in minimizing NMO relapses. Although it is not officially FDA authorized, it is frequently used for NMO.

A medication that inhibits the immune system may also be advised by the healthcare provider. Azithromycin, mycophenolate, methotrexate, cyclophosphamide, or tocilizumab may be among them

Intravenous immunoglobulins, also known as antibodies, have the potential to reduce the rate of NMO relapses.

Doctors who treat this condition